Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4239
Name alveolar soft part sarcoma
Definition A soft tissue cancer that is a slow growing tumor of an unknown origin that effects children and effects young adults.
Source DiseaseOntology.org
Alt Ids DOID:5315 DOID:5318
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer muscle cancer skeletal muscle cancer alveolar soft part sarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00942877 Phase II Cediranib Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma Active, not recruiting USA 0
NCT01391962 Phase II Sunitinib Cediranib Sunitinib or Cediranib for Alveolar Soft Part Sarcoma Active, not recruiting USA 0
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02936102 Phase I FAZ053 FAZ053 + Spartalizumab A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting USA | ITA | FRA | ESP | CAN 4
NCT02978859 Phase II Sitravatinib MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03016819 Phase III Anlotinib Dacarbazine A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS) Recruiting USA | ITA | ESP 2
NCT03141684 Phase II Atezolizumab Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery Recruiting USA 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Recruiting ITA | ESP 1
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Withdrawn USA 0
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Recruiting FRA 0
NCT04332874 Phase II Pembrolizumab A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Recruiting USA 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04595994 Phase I Selinexor Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Recruiting ESP 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT05333458 Phase II Atezolizumab + Selinexor Atezolizumab Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma Recruiting USA 0